Research Analysts Offer Predictions for Verastem Q1 Earnings

Verastem, Inc. (NASDAQ:VSTM) – Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Verastem in a research note issued to investors on Monday, March 24th. HC Wainwright analyst S. Lee anticipates that the biopharmaceutical company will post earnings of ($0.67) per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Verastem’s current full-year earnings is ($3.02) per share. HC Wainwright also issued estimates for Verastem’s Q2 2025 earnings at ($0.74) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.62) EPS, FY2026 earnings at ($1.10) EPS and FY2027 earnings at ($0.33) EPS.

Verastem (NASDAQ:VSTM) last released its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.57).

A number of other research analysts have also recently commented on VSTM. StockNews.com upgraded Verastem from a “sell” rating to a “hold” rating in a research note on Monday. B. Riley increased their price target on shares of Verastem from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. Royal Bank of Canada cut their price objective on shares of Verastem from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday, March 21st. Mizuho boosted their price target on Verastem from $7.00 to $9.00 and gave the stock an “outperform” rating in a research report on Thursday, December 19th. Finally, Guggenheim raised their price objective on Verastem from $13.00 to $14.00 and gave the company a “buy” rating in a research report on Monday. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.88.

Verastem Trading Down 2.6 %

NASDAQ:VSTM opened at $6.40 on Thursday. Verastem has a 12 month low of $2.10 and a 12 month high of $13.52. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 2.77. The company has a 50-day moving average price of $6.10 and a 200-day moving average price of $4.72. The stock has a market cap of $284.84 million, a price-to-earnings ratio of -2.01 and a beta of 0.60.

Institutional Trading of Verastem

A number of hedge funds and other institutional investors have recently modified their holdings of VSTM. Charles Schwab Investment Management Inc. boosted its holdings in Verastem by 46.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 103,601 shares of the biopharmaceutical company’s stock worth $310,000 after buying an additional 32,791 shares during the period. FMR LLC purchased a new position in shares of Verastem in the third quarter valued at about $41,000. Stonepine Capital Management LLC bought a new position in shares of Verastem in the third quarter worth about $3,918,000. Walleye Capital LLC grew its position in shares of Verastem by 493.7% during the third quarter. Walleye Capital LLC now owns 216,126 shares of the biopharmaceutical company’s stock worth $646,000 after purchasing an additional 179,725 shares in the last quarter. Finally, Stifel Financial Corp grew its position in shares of Verastem by 62.3% during the third quarter. Stifel Financial Corp now owns 30,339 shares of the biopharmaceutical company’s stock worth $91,000 after purchasing an additional 11,642 shares in the last quarter. 88.37% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Verastem

In other Verastem news, CEO Dan Paterson sold 8,568 shares of Verastem stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $5.24, for a total transaction of $44,896.32. Following the transaction, the chief executive officer now owns 347,581 shares of the company’s stock, valued at $1,821,324.44. The trade was a 2.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders sold 9,960 shares of company stock worth $53,498. 2.20% of the stock is owned by company insiders.

About Verastem

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.